Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized verapamil for pulmonary hypertension secondary to COPD
ACTRN12612001239853Phase 2Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of verapamil in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH) and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in pulmonary arterial pressure, Change in ejection fraction and 1 more. Started Feb 2012; status: recruiting.
02
Drugs
verapamil
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12612001239853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001239853.